Avidity of serogroup A meningococcal IgG antibodies after immunization with different doses of a tetravalent A/C/Y/W135 polysaccharide vaccine

Hdl Handle:
http://hdl.handle.net/10144/221031
Title:
Avidity of serogroup A meningococcal IgG antibodies after immunization with different doses of a tetravalent A/C/Y/W135 polysaccharide vaccine
Authors:
Bårnes, G K; Naess, L M; Rosenqvist, E; Guerin, P J; Caugant, D A
Journal:
Scandinavian Journal of Immunology
Abstract:
In the absence of an affordable conjugate meningococcal vaccine, mass vaccination campaigns with polysaccharide vaccines are the means to control meningitis epidemics in sub-Saharan Africa. Facing global vaccine shortage, the use of reduced doses, which have been shown to be protective by serum bactericidal activity, can save many lives. In this study, we investigated the antibody responses and avidity of IgG antibodies evoked against the serogroup A capsule of Neisseria meningitidis by different doses of an A/C/Y/W135 polysaccharide vaccine. Volunteers in Uganda were vaccinated with 1/10, 1/5 or a full dose (50 μg) and revaccinated with a full dose after 1 year. Specific IgG geometric mean concentrations and geometric mean avidity indices (GMAI) were determined by a modified enzyme-linked immunosorbent assay (ELISA) using thiocyanate as a chaotropic agent. After vaccination with 1/10 or 1/5 doses, the GMAI increased from 1 month to 1 year. One year following the initial dose, the GMAI levels were higher in the arm receiving reduced doses than for the arm receiving a full dose. Following the second full dose, avidity indices equalized at approximately the same level in the three arms. Although there are practical challenges to the use of reduced doses in the field, our findings suggest that reduced doses of polysaccharide vaccine are able to elicit antibodies of as good avidity against serogroup A polysaccharide as a full dose.
Affiliation:
Department of Bacteriology and Immunology, Norwegian Institute of Public Health, Oslo, Norway; Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway; Department of Infectious Disease Epidemiology, Norwegian Institute of Public Health, Oslo, Norway; Epicentre, Paris, France; Centre for Tropical Medicine, Nuffield Department of Clinical Medicine, University of Oxford, CCVTM, Oxford, UK; Department of International Health, University of Oslo, Oslo, Norway
Publisher:
Blackwell
Issue Date:
8-Jun-2011
URI:
http://hdl.handle.net/10144/221031
DOI:
10.1111/j.1365-3083.2011.02535.x
PubMed ID:
21332570
Additional Links:
http://onlinelibrary.wiley.com/doi/10.1111/j.1365-3083.2011.02535.x/abstract
Type:
Article
Language:
en
ISSN:
1365-3083
Appears in Collections:
Vaccination

Full metadata record

DC FieldValue Language
dc.contributor.authorBårnes, G Ken_GB
dc.contributor.authorNaess, L Men_GB
dc.contributor.authorRosenqvist, Een_GB
dc.contributor.authorGuerin, P Jen_GB
dc.contributor.authorCaugant, D Aen_GB
dc.date.accessioned2012-04-28T17:02:45Z-
dc.date.available2012-04-28T17:02:45Z-
dc.date.issued2011-06-08-
dc.identifier.citationScand J Immunol 2011; 74:87-94en_GB
dc.identifier.issn1365-3083-
dc.identifier.pmid21332570-
dc.identifier.doi10.1111/j.1365-3083.2011.02535.x-
dc.identifier.urihttp://hdl.handle.net/10144/221031-
dc.description.abstractIn the absence of an affordable conjugate meningococcal vaccine, mass vaccination campaigns with polysaccharide vaccines are the means to control meningitis epidemics in sub-Saharan Africa. Facing global vaccine shortage, the use of reduced doses, which have been shown to be protective by serum bactericidal activity, can save many lives. In this study, we investigated the antibody responses and avidity of IgG antibodies evoked against the serogroup A capsule of Neisseria meningitidis by different doses of an A/C/Y/W135 polysaccharide vaccine. Volunteers in Uganda were vaccinated with 1/10, 1/5 or a full dose (50 μg) and revaccinated with a full dose after 1 year. Specific IgG geometric mean concentrations and geometric mean avidity indices (GMAI) were determined by a modified enzyme-linked immunosorbent assay (ELISA) using thiocyanate as a chaotropic agent. After vaccination with 1/10 or 1/5 doses, the GMAI increased from 1 month to 1 year. One year following the initial dose, the GMAI levels were higher in the arm receiving reduced doses than for the arm receiving a full dose. Following the second full dose, avidity indices equalized at approximately the same level in the three arms. Although there are practical challenges to the use of reduced doses in the field, our findings suggest that reduced doses of polysaccharide vaccine are able to elicit antibodies of as good avidity against serogroup A polysaccharide as a full dose.en_GB
dc.language.isoenen
dc.publisherBlackwellen_GB
dc.relation.urlhttp://onlinelibrary.wiley.com/doi/10.1111/j.1365-3083.2011.02535.x/abstracten_GB
dc.rightsArchived with thanks to Blackwell and the Scandinavian Journal of Immunologyen_GB
dc.subject.meshAdolescenten_GB
dc.subject.meshAntibodies, Bacterialen_GB
dc.subject.meshAntibody Affinityen_GB
dc.subject.meshChilden_GB
dc.subject.meshChild, Preschoolen_GB
dc.subject.meshHumansen_GB
dc.subject.meshImmunoglobulin Gen_GB
dc.subject.meshMeningococcal Vaccinesen_GB
dc.subject.meshNeisseria meningitidis, Serogroup Aen_GB
dc.subject.meshRandomized Controlled Trials as Topicen_GB
dc.subject.meshUgandaen_GB
dc.subject.meshVaccinationen_GB
dc.subject.meshYoung Adulten_GB
dc.titleAvidity of serogroup A meningococcal IgG antibodies after immunization with different doses of a tetravalent A/C/Y/W135 polysaccharide vaccineen
dc.typeArticleen
dc.contributor.departmentDepartment of Bacteriology and Immunology, Norwegian Institute of Public Health, Oslo, Norway; Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway; Department of Infectious Disease Epidemiology, Norwegian Institute of Public Health, Oslo, Norway; Epicentre, Paris, France; Centre for Tropical Medicine, Nuffield Department of Clinical Medicine, University of Oxford, CCVTM, Oxford, UK; Department of International Health, University of Oslo, Oslo, Norwayen_GB
dc.identifier.journalScandinavian Journal of Immunologyen_GB
All Items in MSF are protected by copyright, with all rights reserved, unless otherwise indicated.